“Fisetin, like many plant polyphenols, is known to have antioxidant properties and demonstrates the specific biological activity of protecting functional macromolecules against stress, resulting in a benefit to cellular cytoprotection. It is also known to have anti-inflammatory, chemopreventive, and chemotherapeutic properties.
Finally, more recently, it has also shown promise as a senolytic, a compound that encourages aged or damaged senescent cells to destroy themselves rather than lingering in the body and contributing to the chronic, age-related inflammation known as “inflammagingâ€, which is associated with a wide range of age-related diseases.
Since fisetin has a good safety profile, Mayo Clinic followed these mouse studies by launching three trials to see if the compound is effective for humans.”
Human Clinical Trials with Fisetin:
- Nov 2018 to April 2020 Alleviation by Fisetin of Frailty, Inflammation, and Related Measures in Older Adults
- Feb 2018 to June 2020 Alleviation by Fisetin of Frailty, Inflammation, and Related Measures in Older Women
- Jan 2018 to April 2022 Inflammation and Stem Cells in Diabetic and Chronic Kidney Disease
